Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

127.31 +2.95 (+2.37%)
Official Closing Price Updated: 7:00 PM EST, Nov 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
52 53 Next >
News headline image
Health Insurer Centene Streamlines - Plans Massive Layoffs To Cut Costs: Report ↗
Centene Corporation (NYSE: CNC) is reportedly laying off about 3% of its workforce as the health insurer plans to cut expenditures and accelerate profits over the years. 
Via Benzinga
Topics Workforce
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 25, 2023 ↗
 
Via Benzinga
News headline image
Amazon Invests $4B In ChatGPT Competitor, Hollywood Writers Accept Tentative Deal, ChatGPT Challenges Siri And Alexa With Introduction Of Verbal Responses: Today's Top Stories ↗
Benzinga 
Via Benzinga
News headline image
2 Dividend Stocks to Buy and Hold Forever ↗
These companies' prospects look secure. 
Via The Motley Fool
News headline image
Price Over Earnings Overview: Novartis ↗
 
Via Benzinga
News headline image
Novartis Sandoz Prepares For Public Debut With Strong Sales Record And Plans for New Biologic Drugs ↗
Novartis AG (NYSE: NVS) confirmed its plans for a 100% spin-off of the Sandoz business on October 4 after shareholders approved it  
Via Benzinga
News headline image
Are Gene Therapy Stocks The Market's Next Big Winners?
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Novartis Precision Cancer Therapy Hits Primary Goal In Rare Type Of Pancreatic Cancer ↗
Novartis AG (NYSE: NVS) released topline data from the Phase 3 NETTER-2 trial with Lutathera, a radioligand therapy (RLT) for advanced gastroenteropancreatic  
Via Benzinga
News headline image
Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement ↗
Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. The company will make... 
Via Talk Markets
News headline image
Peering Into Novartis's Recent Short Interest ↗
 
Via Benzinga
News headline image
AI To Revolutionize Clinical Trials And Diagnostics ↗
With the help of technology, the pharmaceutical industry is gaining new insights that are fueling the development of next generation of drugs while also speeding up clinical trials and improving... 
Via Benzinga
Topics Artificial Intelligence
News headline image
From Years to Months: How AI is Shaping the Landscape of Clinical Trials ↗
Pharmaceutical companies are harnessing artificial intelligence (AI) to speed up the traditionally arduous process of clinical trials, potentially saving both time and significant sums of money. These... 
Via Benzinga
Topics Artificial Intelligence
News headline image
Preventable Vaccines Market May See a Big Move : AstraZeneca, GlaxoSmithKline, Merck
Stay up-to-date with Preventable Vaccines Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
News headline image
Amazon Poaches Microsoft's Product Chief, Google And DoD Team Up For AI-Powered Microscope To Identify Cancer, Rocket Lab's 41st Mission Succumbed To Technical Issues: Today's Top Stories ↗
Bloomberg 
Via Benzinga
News headline image
Chinese Drugmaker BeiGene And Novartis Move Out From Second Cancer Drug Pact ↗
BeiGene Ltd (NASDAQ: BGNE) said it would regain rights to develop, manufacture, and commercialize Tevimbra (tislelizumab), its cancer drug, from Novartis AG (NYSE: NVS). 
Via Benzinga
News headline image
AMC Stock Alert: Adam Aron Teases New Chocolate, Wine Brands for AMC ↗
AMC Entertainment (AMC) stock is a hot topic on Friday after the movie theater chain's CEO teased that new products are on the way. 
Via InvestorPlace
News headline image
Why Is Canopy Growth (CGC) Stock Up 14% Today? ↗
Canopy Growth (CGC) stock is rising higher on Friday after the cannabis company announced it won't fund BioSteel Sports Nutrition any longer. 
Via InvestorPlace
Topics Cannabis
News headline image
NVS Stock Alert: Novartis Shareholders Approve Sandoz Spinoff ↗
Novartis (NVS) stock is rising higher on Friday after the company announced approval for the spinoff of its generic drugs business Sandoz. 
Via InvestorPlace
News headline image
Instacart Mulls IPO Price Hike After Arm's Stellar Debut, UAW Launches Historic Simultaneous Strike, China Sanctions Lockheed Martin & Northrop Grumman Concerning Taiwan Arms Sales: Today's Top Stories ↗
Wall Street Journal 
Via Benzinga
Topics Initial Public Offering
News headline image
Have Million-Dollar Gene Therapies Finally Reached An Inflection Point? ↗
Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions. 
Via Investor's Business Daily
News headline image
Sandoz Pushes Product Launch Plans As Novartis Shareholders Approve The Spin-Off ↗
At an Extraordinary General Meeting, Novartis AG's (NYSE: NVS) shareholders  
Via Benzinga
News headline image
AI Integration In Biotech & Pharma: Companies Positioned To Benefit ↗
The convergence of artificial intelligence (AI) with the biotech and pharmaceutical sectors is ushering in a new era of innovation. AI is catalyzing transformations from drug discovery to patient care.... 
Via Benzinga
Topics Artificial Intelligence
News headline image
Qualcomm-Apple's Chip Supply Agreement, Alleged Report About AstraZeneca CEO Sir Pascal Soriot's Intention To Step Down, Apple & Google Face Off in Antitrust Showdown: Today's Top Stories ↗
Benzinga Qualcomm Announces Chip Supply Agreement With Apple 
Via Benzinga
News headline image
Another Arthritis Blockbuster Drug Faces Generic Competition: Novartis' Sandoz Inks Pact With Samsung Bioepis ↗
Sandoz, a generic and biosimilar medicines unit of Novartis AG (NYSE: NVS), has  
Via Benzinga
News headline image
AI 2.0 is Here: How to Invest in a Generational Opportunity
AI is sweeping the world but don't confuse apples with oranges; here's a look at the top 5 advancements in AI and who is using it. 
Via MarketBeat
Topics Artificial Intelligence Supply Chain
News headline image
Could This Biosimilar Drug Be Novartis' Next Blockbuster? ↗
Novartis expects to submit regulatory applications for its biosimilar soon. 
Via The Motley Fool
News headline image
8 Pharma Stocks Affected by New Drug Price Negotiation Rules ↗
Which companies have the most to lose now that Medicare can negotiate directly with them on the prices of some of the most widely used drugs? 
Via The Motley Fool
News headline image
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects. 
Via MarketBeat
Topics Economy
News headline image
Biden Administration Vs. Big Pharma: What the Legal Showdown Means for Your Wallet ↗
The Biden administration's move to lower drug prices has prompted a flurry of legal challenges. 
Via Benzinga
News headline image
Sex Hormones Market to See Huge Growth by 2028 : Novartis, Sanofi, AstraZeneca, Merck
Sex Hormones- Comprehensive Study by Type (Progesterone, Testosterone, Drospirenone), Application (Topical, Inhalation, Injection, Others) Players and Region - Global Market Outlook to 2027 
Via SBWire
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
52 53 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.